Brean Murray Carret & Co. Starts IntelliPharmaCeutics International (IPCI) at Buy

September 11, 2012 7:18 AM EDT Send to a Friend
Get Alerts IPCI Hot Sheet
Price: $2.80 +2.94%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 18 | New: 41
Trade IPCI Now!
Join SI Premium – FREE
Brean Murray Carret & Co. initiates coverage on IntelliPharmaCeutics International (NASDAQ: IPCI) with a Buy. PT $7.00.

Brean analyst said, "We see several near-term catalysts for Intellipharmaceutics, notably its second Phase 1 Rexista dataset, a potential Rexista partnership, and initiation of Phase 3 Rexista trials. Positive Phase 1 data for Rexista could lead to a partnership that generates a significant upfront payment. Also, Phase 3 initiation, expected in 1Q13, would clarify Rexista’s potential market timing."

For an analyst ratings summary and ratings history on IntelliPharmaCeutics International click here. For more ratings news on IntelliPharmaCeutics International click here.

Shares of IntelliPharmaCeutics International closed at $2.86 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage

Related Entities

Brean Murray Carret & Co.

Add Your Comment